EUVIMEDEUVIMED entdecken
Open Access

Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

Lachelle D Weeks, Abhishek Niroula, Donna Neuberg, Waihay Wong, R Coleman Lindsley, Marlise Luskin, Nancy Berliner, Richard M Stone, Daniel J DeAngelo, Robert Soiffer, Md Mesbah Uddin, Gabriel Griffin und 7 weitere

NEJM Evidence · 25.04.2023 · 2 (5)

DOI: 10.1056/evidoa2200310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NEJM Evidence, erschienen am 25.04.2023. Verfasst von Lachelle D Weeks und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Die Arbeit wurde bisher 346-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) are defined by somatic mutations in genes associated with myeloid neoplasms (MN) at a variant allele fraction (VAF) ≥ 0.02, in the absence and presence of cytopenia, respectively. CHIP/CCUS is highly prevalent in adults and defining predictors of MN risk would aid clinical management and research.

Methods

We analyzed sequenced exomes of healthy UK Biobank (UKB) participants (n = 438,890) in separate derivation and validation cohorts. Genetic mutations, laboratory values, and MN outcomes were used in conditional probability-based recursive partitioning and Cox regression to determine predictors of incident MN. Combined statistical weights defined a clonal hematopoiesis risk score (CHRS). Independent CHIP/CCUS patient cohorts were used to test prognostic capability of the CHRS in the clinical setting.

Results

Recursive partitioning distinguished CHIP/CCUS cases with 10-year probabilities of MN ranging from 0.0078 - 0.85. Multivariable analysis validated partitioning variables as predictors of MN. Key features, including single DNMT3A mutations, high risk mutations, ≥ 2 mutations, VAF ≥ 0.2, age ≥ 65 years, CCUS vs CHIP and red blood cell indices, influenced MN risk in variable direction. The CHRS defined low risk (n = 10018, 88.4%), intermediate risk (n = 1196, 10.5%), and high risk (n = 123, 1.1%) groups. In clinical cohorts, most MN events occurred in high risk CHIP/CCUS patients.

Conclusions

The CHRS provides simple prognostic framework for CHIP/CCUS, distinguishing a high risk minority from the majority of CHIP/CCUS which has minimal risk for progression to MN.

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Medicine, Harvard Medical School, Boston, MA.
  • Center for Prevention of Progression, Dana-Farber Cancer Institute, Boston, MA.
  • Broad Institute of MIT and Harvard University, Cambridge, MA.
  • Department of Lab Medicine, Lund University, Lund, Sweden.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Weeks, L. D., Niroula, A., Neuberg, D., Wong, W., Lindsley, R. C., Luskin, M., Berliner, N., Stone, R. M., DeAngelo, D. J., Soiffer, R., Uddin, M. M., Griffin, G., Vlasschaert, C., Gibson, C. J., Jaiswal, S., Bick, A. G., Malcovati, L., Natarajan, P., & Ebert, B. L. (2023). Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis. NEJM Evidence, 2(5). https://doi.org/10.1056/evidoa2200310

Vancouver

Weeks LD, Niroula A, Neuberg D, Wong W, Lindsley RC, Luskin M, et al. Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis. NEJM Evidence. 2023;2(5). doi:10.1056/evidoa2200310

BibTeX
@article{Weeks2023,
  author = {Weeks, Lachelle D and Niroula, Abhishek and Neuberg, Donna and Wong, Waihay and Lindsley, R Coleman and Luskin, Marlise and Berliner, Nancy and Stone, Richard M and DeAngelo, Daniel J and Soiffer, Robert and Uddin, Md Mesbah and Griffin, Gabriel and Vlasschaert, Caitlyn and Gibson, Christopher J and Jaiswal, Siddhartha and Bick, Alexander G and Malcovati, Luca and Natarajan, Pradeep and Ebert, Benjamin L},
  title = {Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis},
  journal = {NEJM Evidence},
  year = {2023},
  volume = {2},
  number = {5},
  doi = {10.1056/evidoa2200310}
}
Kostenlos starten →